NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Alamar Biosciences, Inc. (ALMR) Stock Analysis

Alamar Biosciences, Inc. (ALMR) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

ALMR

$30.80

+$0.23 (+0.75%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALMR with… →

ALMR Key Statistics

As of Sep 4, 2026
Trading
Open
$30.17
Previous Close
$30.57
Day's Range
29.83–31.06
52-Week Range
18.85–38.54
Volume
142.90K
Valuation
Market Cap
$2.14B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
21.28
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.72
Financials (FY)
Revenue (FY)
$74.21M+195.17%
Net Income (FY)
−$29.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
−49.45%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
69.39M
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
333.08K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ALMR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$74.21M−$29.82M−40.2%
2024$25.14M−$47.07M−187.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$74.21M$41.71M−$31.33M−$29.82M−40.2%
2024$25.14M$8.61M−$49.57M−$47.07M−187.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALMR Valuation vs Medical Devices Median

Median of 151 stocks
MetricALMRMedical Devices medianvs median
P/S ratio21.282.987.2x the median
Profit margin−49.45%−1.69%47.8 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alamar Biosciences, Inc. (ALMR) carries a market capitalisation of $2.14B. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 286.

The 52-week range on file runs from $18.85 to $38.54. The most recent close on file for ALMR is $30.80, dated September 4, 2026. That is +$0.23 (+0.75%) against the previous close. The latest close sits 63.4% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $74.21M. Against the prior fiscal year total of $25.14M, that is a change of +195.17%. The same year closed with a net loss of $29.82M. The reported profit margin is −49.45%. That is 47.8 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.72.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 21.28 times revenue. On price-to-sales that is 7.2 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Growth & Income

No dividend is on file for ALMR.

2026 is still running; the price is +40.00% year to date.

Peer Comparison

Alamar Biosciences, Inc. (ALMR) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alamar Biosciences, Inc. ALMR $2.14B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Alamar Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Alamar Biosciences, Inc.

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.

Visit website →